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Previewsinteraction with ETS1, a critical compo-
nent of the complex that binds and acti-
vates Ea (Figure 1). To test the biological
significance of this interaction on the
enhancer element, the authors silenced
TLX1/3 in human T-ALL cell lines and
observed increases in differentiation and
cell death, suggesting abortive differenti-
ation and induction of apoptosis. Ectopic
expression of rearranged TCRa caused
identical effects. These findings therefore
connect proper TCR rearrangement and
expression to tumor differentiation state.
Altogether, the work of Dadi et al. (2012)
presents a novel mechanism of differenti-
ation arrest orchestrated by the TLX
oncogenes in the induction and mainte-
nance of T-ALL. To this end, it will be
important to determinewhether additional
transcriptional targets that are potentially
perturbed by TLX1/3 are also important
for progression of the disease. This is an
important question as the differentiation
defects seen in TLX1 transgenic mice
are distinct from those caused by
paucity of TCRa rearrangement in human
leukemia. One such example could be the
downregulation BCL11B, a target of TLX1that is essential for T cell commitment.
Further investigation on the potential
synergistic role other factors play in the
TCR recombination (Polycomb complex,
the CTCF insulator protein, and others)
and on the mechanisms leading to sus-
tained expression of the TLX proteins
will shed light on the intricacies of this
leukemia. Ultimately, the most intriguing
implication of this study is whether there
are means of regulating TLX function
using targeted therapies to enforce differ-
entiation of TLX1/3+ T-ALL. A similar
approach of ‘‘differentiation therapy’’ has
been extremely effective in the treatment
of acute promyelocytic leukemia with all-
trans retinoic acid (Kogan and Bishop,
1999). Given that their expression is
normally restricted to embryonic develop-
ment, TLX1/3 could prove to be ideal
targets in the treatment of large fraction
T cell leukemias with limited potential for
adverse side effects.REFERENCES
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Two recent papers published in Nature demonstrate the power of systematic high-throughput pharmaco-
logic profiling of very large, diverse, molecularly-characterized human cancer cell line panels to reveal link-
ages between genetic profile and targeted-drug sensitivity. Known oncogene addictions are confirmed while
surprising complexities and biomarker relationships with clinical potential are revealed.The need to identify predictive biomarkers
of tumor response has intensified with
the era of molecularly-targeted therapies
that exploit addictions and vulnerabilities
in tumorswith identifiablemolecular traits,
in contrast to the one-size-fits-all ap-proach that dominated cytotoxic chemo-
therapy (Yap and Workman, 2012). Two
recent Nature articles describe a system-
atic large-scale approach to this challenge
by high-throughput profiling many tar-
geted agents against hundreds of clini-cally-relevant human cancer cells lines
with detailed genetic annotation (Garnett
et al., 2012; Barretina et al., 2012).
There are three important general take-
home messages from these two studies.
(1) The articles provide themost extensivel 21, April 17, 2012 ª2012 Elsevier Inc. 455
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scale analyses of human tumor cell panels
that link drug sensitivity to cancer cell
genetics. (2) They reveal examples of
previously unsuspected genetic-pharma-
cologic relationships and complexities,
some with immediate clinical potential.
(3) They make available publicly the
pharmacologic screening data alongside
extensive genetic and other molecular
characterization of the cancer cell
panel (http://www.broadinstitute.org/ccle;
http://www.cancerrxgene.org/), providing
powerful tools and resources for use by
the cancer community. Researchers can
now mine the datasets to generate and
test hypotheses, while new compounds
can be submitted to the panel screens for
pharmacogenomic interrogation.
A caveat of these studies is that both
use the artificial two-dimensional ad-
herent growth of established cancer cell
lines on plastic and also lack the environ-
mental and cellular complexity of clinical
cancers. Nevertheless, very large diverse
cancer cell line panels provide the only
means currently available with which to
model the enormous genetic and epige-
netic heterogeneity present in human
cancers and hence to identify predictive
response biomarkers that address the
molecular diversity seen in the clinic
(Caponigro and Sellers, 2011).
The systematic large-scale pharmaco-
logic and genetic analysis approach
has its origins in the pioneering NCI60
tumor cell line panel (Weinstein et al.,
1997). This led to use of larger cancer
cell line panels that identified genotype-
correlated sensitivity to kinase inhibitors
within and between cancer histologies.
However, it became clear that hundreds
of cancer cell lines must now be used
to mimic clinical heterogeneity and to
account for pathogenic driver mutations
present in only, say, 5% or even less of
cancers (Caponigro and Sellers, 2011;
Garnett and McDermott, 2012).
Figure 1A summarizes the workflow
used for the two studies. Several clear
high-level trends emerge from the anal-
ysis. Certain agents, e.g., the microtubule
stabilizer paclitaxel and the pan-histone
deacetylase inhibitor panobinostat, show
broad activity whereas a few, including
p53-MDM2 antagonists, are active in a
small minority of cancer cell lines. Outlier
cell lines with unusual sensitivity are often
informative. Sensitivity to most agents456 Cancer Cell 21, April 17, 2012 ª2012 Elsis associated with at least one gene
mutation, importantly demonstrating the
very broad potential applicability of
predictive biomarkers. Known oncogene
addiction paradigms are reconfirmed
in the large scale panels for several
approved or developmental kinase inhibi-
tors, including those targeting BCR-ABL,
BRAF, MEK, ALK, ERBB2, EGFR, FLT3,
and PIK3CA. Interestingly, however,
gene expression features often correlate
as well or even better with sensitivity
than kinase mutation. Furthermore,
mutation-sensitivity relationships are
frequently modified by tissue-specific or
gene expression biomarkers, suggesting
the need for multigene signatures of
sensitivity and reinforcing the importance
of mechanistic drug combinations.
Some specific examples are illustrative
(Figure 1B). Both studies conclusively
demonstrate that expression of the
quinone reductase metabolizing enzyme
NQO1 was the strongest predictor of
sensitivity to the benzoquinone ansamy-
cin HSP90 molecular chaperone inhibitor
17-AAG (tanespimycin), as initially dis-
covered using the NCI60 panel (Kelland
et al., 1999), but not to the non-quinone
chemotype NVP-AUY922, thus exempli-
fying differences in predictors between
chemotypes hitting the same target.
The now clinically-validated synthetic-
lethal relationship between inhibitors of
the DNA repair enzyme poly(ADP-ribose)
polymerase (PARP) and BRCA mutations
could not be revealed in the short,
3 day drug exposures used. Thus other
synthetic lethal relationships might also
be missed. However, Garnett et al. (2012)
do confirm the very recent discovery that
PARP inhibitors (here olaparib and AG-
014699) are highly active against Ewing’s
sarcoma cells with the characteristic
EWS-FLI1 rearrangement (Brenner et al.,
2012), analogous to the sensitivity to
PARP inhibition of prostate cancer cells
with related ETS gene fusions (Brenner
et al., 2011). Sensitivity may relate to
PARP1 acting as a cofactor for the tran-
scriptional activity of ETS family proteins
or to a known EW1-FLI1-PARP positive
feedback loop in transcriptional activation.
Although sensitivity does not appear to be
due to a defective DNA damage response
per se, PARP inhibition may potentiate
EST-mediated DNA damage. Thus there
is exciting potential for evaluating PARP
inhibitors in Ewing’s sarcoma patients.evier Inc.An unexpected and unexplained finding
is that expression of SLFN11, encoding
a member of the schlafen family of pro-
teins with unknown function, is predictive
of sensitivity to two camptothecin-based
topoisomerase I inhibitors in several
cancer cell lineages including, again,
Ewing’s sarcoma lines (Barretina et al.,
2012). Clinical trials with topoisomerase
inhibitors are already underway in Ewing’s
sarcoma.
BRAF and NRAS mutations are recon-
firmed in both large-scale studies as
single-gene predictors of sensitivity to
MEK inhibitors. Expression of a group of
genes, including those encoding known
regulators of MAP kinase signaling,
is found to modulate MEK inhibitor sensi-
tivity. A novel observation is that expres-
sion of the aryl hydrocarbon receptor
gene (AHR) strongly correlates with sensi-
tivity to MEK inhibition in cancer cells with
NRAS mutations and may be a predictive
biomarker for increasedMEK sensitivity in
such cancers (Barretina et al., 2012). The
causal link was confirmed by AHR
silencing, which suppresses the growth
of high but not low AHR expressing
NRAS mutant cancer lines. Interestingly,
Garnett et al. (2012) find that resistance
to MEK inhibitors is also associated with
the driver EWS-FLI1 translocation.
Our own preliminary analysis of these
data sets reveals, with a few notable
exceptions, a surprising lack of correlation
between the cellular effects of groups of
drugs that supposedly have the same
primary molecular mechanism, indicat-
ing polypharmacology and complex re-
sponse drivers other than the declared
targets. Interestingly, among the excep-
tions that are tightly correlated, the highly
selective MEK inhibitors AZD-6244 and
PD-0325901 show identical effector
gene associations. In contrast, PARP and
HSP90 inhibitors exhibit different effector
gene associations that suggest a more
complex basis for their action (Figure 1B).
For most drugs, sensitive cell lines are
distributed across multiple cancer types.
However, both articles show examples
of cell lineage, rather than genetics, being
the predominant predictive feature.
Multiple myeloma cell lines with elevated
IGF1 and IGF1R expression exhibit
enhanced sensitivity to an IGF-1 receptor
inhibitor, renal cell carcinomas to SRC
inhibitors, and gliomas to a ROCK inhib-
itor. A hematologic lineage was predictive
Figure 1. Systematic Large-Scale Pharmacologic and Genetic Profiling of Extensive Human Cancer Cell Line Panels
(A) Schematic of the workflow for screening human tumor cell line panels to identify factors that influence response to small-molecule drugs or tool compounds. A
library of compounds (a) was screened in microplate format (b) against a diverse panel of cancer cell lines using an eight- to nine-point dose-response curve (c)
fromwhich sensitivities were calculated either as the concentration causing half-maximal inhibition of growth (IC50) or from the slope of the responsive part of the
curve. This generated a response profile across the cancer cell line panel for each compound (d). Garnett et al. (2012) profiled 130 agents against 275–507 cancer
cell lines using a nine-point dose-response following 72 hr continuous exposure to compounds and assessed sensitivity by cell fixation and staining with a fluo-
rescent DNA-binding dye as the end-point. Barretina et al. (2012) assessed 24 compounds across a panel of 479 tumor cell lines with an eight-point dose-
response and measured total ATP using a luciferase-based assay following 72–84 hr continuous exposure. The sensitivity profile was then correlated with
genomic features (e), gene expression patterns (f), or oncogenic mutations (g) using statistical methods. Both groups used the same chip-based methodology
to determine single nucleotide polymorphism status and gene copy number. Garnett et al. (2012) profiled expression of 14.5k genes using oligonucleotide-based
microarray technology. Barretina et al. (2012) profiled more genes with a later version of the same system. Point mutation status was determined by capillary
sequencing of all coding exons for 64 genes frequently mutated in cancer by Garnett et al. (2012) or by targeted massively parallel sequencing of 1651 protein
coding genes by Barretina et al. (2012) (h) Distribution of mechanistic classes of tested compounds in Barretina et al. (2012) (left) and Garnett et al. (2012) (right).
(B) Examples of targeted drugs and corresponding effector genes identified in the two studies to be associated with sensitivity (blue lines) or resistance (red lines).
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Previewsof panobinostat sensitivity, in agreement
with the majority of clinical responses to
panobinostat and other HDAC inhibitors
being in hematological cancers.
Overall, these two important new
studies firmly establish the value of
systematic large-scale automated human
cancer cell panel profiling for discovering
cancer cell vulnerabilities, defining the
cellular mechanism of action of small-
molecule inhibitors, and identifying pre-dictive biomarkers. The analytical power
of the panels will grow as more com-
pounds are profiled, including the impor-
tant need to confirm biological associa-
tions using compounds of diverse
chemotypes that hit the same target
(Workman and Collins, 2010) and will
also increase as the depth of genetic
annotation rises, with the planned inclu-
sion of the sequencing data for the coding
exons of all22,000 human genes (Capo-Cancer Celnigro and Sellers, 2011; Garnett and
McDermott, 2012). Additional cancer cell
line annotations, including epigenomic,
proteomic, and metabolomic features,
would add further mechanistic and pre-
dictive power. Future iterations of the
screens could involve use of more physio-
logical growth conditions and longer
incubation times.
Thus patient-predictive human cancer
cell panels are set to become anl 21, April 17, 2012 ª2012 Elsevier Inc. 457
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Previewsincreasingly powerful platform for
systematic mechanistic studies and
especially for biomarker discovery. This,
in turn, will facilitate the development
and widespread application of personal-
ized cancer medicine.REFERENCES
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